Related Experiment Video
Updated: Dec 8, 2025
Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
Published on: January 28, 2019
Acupoint application for rotavirus diarrhea in infants and children: A protocol for systematic review and meta
Shaodan Sun1, Xiaojie Lin2, Yang Yang3
1Department of Pediatrics, The First Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine.
Insights
Acupoint application may be an effective treatment for rotavirus diarrhea in children, offering a potentially better alternative to conventional therapies. This systematic review assesses its safety and efficacy in pediatric patients.
Area of Science:
- Pediatrics
- Gastroenterology
- Traditional Chinese Medicine
Background:
- Diarrheal disease causes significant child mortality globally, with rotavirus being a primary culprit.
- Current Western medical treatments for rotavirus diarrhea often lack satisfactory efficacy and face compliance challenges in infants and children.
- Acupoint application shows promise in increasing clinical cure rates and reducing diarrhea duration.
Purpose of the Study:
- To systematically review and evaluate the safety and efficacy of acupoint application for treating rotavirus diarrhea in infants and children.
- To address the lack of comprehensive systematic reviews on this specific intervention.
Main Methods:
- Comprehensive literature search across multiple databases (PubMed, EMBASE, Web of Science, etc.) up to August 2020.
- Inclusion of randomized controlled trials (RCTs) with no language restrictions.
- Independent study review, data extraction using RevMan V 5.0, and methodological quality assessment per Cochrane Handbook.
Main Results:
- The study aims to synthesize findings from included RCTs.
- Results will be published in a peer-reviewed journal, detailing the evidence base.
Conclusions:
- This systematic review will determine if acupoint application is a safe and effective intervention for pediatric rotavirus diarrhea.
- Findings will inform clinical practice and future research directions.
Background:
Diarrheal disease currently claims the lives of approximately 500,000 children each year. Rotaviruses are the pathogens primarily responsible for more severe cases and more than one-third of diarrhea-associated deaths in children under 5 years old globally. At present, commonly used drug therapies for rotavirus diarrhea in Western medicine, such as oral rehydration salts, montmorillonite, probiotics, and nitazoxanide, often cannot achieve satisfactory curative effects. Moreover, infants' and children's compliance with drugs and injections is often lower than their compliance with acupoint application therapy. A large number of studies have shown that acupoint application can increase the clinical cure rate and shorten the duration of diarrhea. However, there is a lack of systematic reviews on the safety and efficacy of acupoint application in the treatment of rotavirus diarrhea. Therefore, we will conduct a study to evaluate the safety and efficacy of acupoint application for rotavirus diarrhea in infants and children.
Methods:
We will search the relevant medical literature using PubMed, EMBASE, Web of Science, Cochrane CENTRAL, China National Knowledge Infrastructure, the Wanfang Database, the Chinese Biomedical Literature Database, and the Chinese Scientific Journal Database from inception to August 2020. Both MeSH and free text terms will be utilized to obtain the maximum numbers of papers. No language restrictions will be applied, and the publication type will be limited to randomized controlled trials. Two teams will independently review and assess the studies for inclusion in the review. RevMan V 5.0 software will be applied for data extraction. The methodological quality of the included studies will be evaluated according to the Cochrane Handbook.
Results:
The results of this study will be published in a peer-reviewed journal.
Conclusion:
The conclusion of this systematic review will provide evidence regarding whether acupoint application is an effective intervention for infants and children with rotavirus diarrhea.
Inplasy Registration Number:
INPLASY202070123.
Related Concept Videos
01:29Drug Dosing: Infants and Children
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...